Education
About Us
Working with TipRanks
Follow Us
Aura Biosciences Inc (AURA)
NASDAQ:AURA
AURA Analyst Ratings
Strong Buy
4 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
AURA Stock 12 Month Forecast
Average Price Target
$19.33
▲(195.57% Upside)
| Highest Price Target$23.00 | Average Price Target$19.33 | Lowest Price Target$13.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Evercore ISI
$20→$13
Buy
98.78%
Upside
Initiated
11/26/25
LifeSci Capital
$23
Buy
251.68%
Upside
Reiterated
11/14/25
Buy Rating on Aura Biosciences Inc. Driven by Promising Pipeline and Strategic Expansion in Ocular OncologyYesterday, Aura Biosciences (Nasdaq: AURA) reported Q3 2025 earnings and provided a business update. Aura's bel-sar (also referred to as AU-011), is a cancer cell targeng , virus like parcle (VLP) conjugated to a light-acv atable drug payload. The therapy is designed for a dual mechanism of acon of (1) dir ect tumor cell necrosis and (2) an immune response via immunogenic cell death and immunogenicity of the VLP backbone.
H.C. Wainwright
$22
Buy
236.39%
Upside
Reiterated
11/14/25
Aura Biosciences Inc: Strong Buy Rating Backed by Promising Clinical Progress and Strategic Oncology ExpansionValuation and risks to achievement of price target. Our 12-month price target of $22 is based on an equally weighted composite of (a) $24.63/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $4.00 discounted at 14% and (b) an NPV of $20/ share (discount rate 12.0%, growth rate 2.0%). The assumptions are in line with the expected P/E multiple and discount rate of an early development-stage biopharmaceutical company. Risks to achieving our price target include the following: 1) Clinical risk.
TD Cowen
―
Buy
―
Reiterated
11/13/25
Leerink Partners
$22
Buy
236.39%
Upside
Reiterated
08/13/25
Optimistic Buy Rating for Aura Biosciences Inc: Promising Pipeline, Strategic Positioning, and Strong FinancialsWe spoke to management who indicated that a meaningful proportion (~1/3 - Reason for report: EARNINGS $22.00 52-Week High – Low: $12.38 - $4.35 Shares Outstanding (mil): 62.0 Market Capitalization (mil): $448.3 Yes Dividend (ann): $0.00 0.0% Dec Yr 2024A 2025E (New) 2025E (Old) 2026E (New) 2026E (Old) Q1 0.0 0.0A -- -- -- Q2 0.0 0.0A -- -- -- Q3 0.0 0.0 -- -- -- Q4 0.0 0.0 -- -- -- FY Rev 0.0 0.0 -- 0.0 -- Q1 ($0.40) ($0.55)A -- -- -- ($0.53) -- -- ($0.51) -- -- ($0.56) -- -- FY EPS ($1.75) ($1.98) ($2.14) ($2.30) ($2.49) P/E NM NM NM NM NM Andrew Berens, M.D.
Citizens JMP
$19
Buy
190.52%
Upside
Reiterated
05/23/25
Scotiabank
$23
Buy
251.68%
Upside
Reiterated
05/16/25
Analyst Type
Any
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Evercore ISI
$20→$13
Buy
98.78%
Upside
Initiated
11/26/25
LifeSci Capital
$23
Buy
251.68%
Upside
Reiterated
11/14/25
Buy Rating on Aura Biosciences Inc. Driven by Promising Pipeline and Strategic Expansion in Ocular OncologyYesterday, Aura Biosciences (Nasdaq: AURA) reported Q3 2025 earnings and provided a business update. Aura's bel-sar (also referred to as AU-011), is a cancer cell targeng , virus like parcle (VLP) conjugated to a light-acv atable drug payload. The therapy is designed for a dual mechanism of acon of (1) dir ect tumor cell necrosis and (2) an immune response via immunogenic cell death and immunogenicity of the VLP backbone.
H.C. Wainwright
$22
Buy
236.39%
Upside
Reiterated
11/14/25
Aura Biosciences Inc: Strong Buy Rating Backed by Promising Clinical Progress and Strategic Oncology ExpansionValuation and risks to achievement of price target. Our 12-month price target of $22 is based on an equally weighted composite of (a) $24.63/share, as a 20x multiple of taxed and diluted FY34 GAAP EPS of $4.00 discounted at 14% and (b) an NPV of $20/ share (discount rate 12.0%, growth rate 2.0%). The assumptions are in line with the expected P/E multiple and discount rate of an early development-stage biopharmaceutical company. Risks to achieving our price target include the following: 1) Clinical risk.
TD Cowen
―
Buy
―
Reiterated
11/13/25
Leerink Partners
$22
Buy
236.39%
Upside
Reiterated
08/13/25
Optimistic Buy Rating for Aura Biosciences Inc: Promising Pipeline, Strategic Positioning, and Strong FinancialsWe spoke to management who indicated that a meaningful proportion (~1/3 - Reason for report: EARNINGS $22.00 52-Week High – Low: $12.38 - $4.35 Shares Outstanding (mil): 62.0 Market Capitalization (mil): $448.3 Yes Dividend (ann): $0.00 0.0% Dec Yr 2024A 2025E (New) 2025E (Old) 2026E (New) 2026E (Old) Q1 0.0 0.0A -- -- -- Q2 0.0 0.0A -- -- -- Q3 0.0 0.0 -- -- -- Q4 0.0 0.0 -- -- -- FY Rev 0.0 0.0 -- 0.0 -- Q1 ($0.40) ($0.55)A -- -- -- ($0.53) -- -- ($0.51) -- -- ($0.56) -- -- FY EPS ($1.75) ($1.98) ($2.14) ($2.30) ($2.49) P/E NM NM NM NM NM Andrew Berens, M.D.
Citizens JMP
$19
Buy
190.52%
Upside
Reiterated
05/23/25
Scotiabank
$23
Buy
251.68%
Upside
Reiterated
05/16/25
Best Analysts Covering Aura Biosciences Inc
1 Month
xxx
Success Rate
5/13 ratings generated profit
Average Return
-3.12%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 38.46% of your transactions generating a profit, with an average return of -3.12% per trade.
3 Months
xxx
Success Rate
12/21 ratings generated profit
Average Return
-1.45%
reiterated a xxx
rating 7 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of -1.45% per trade.
1 Year
Success Rate
4/13 ratings generated profit
Average Return
-9.67%
reiterated a buy rating 7 months ago
Copying George Farmer's trades and holding each position for 1 Year would result in 30.77% of your transactions generating a profit, with an average return of -9.67% per trade.
2 Years
xxx
Success Rate
2/11 ratings generated profit
Average Return
-19.13%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 18.18% of your transactions generating a profit, with an average return of -19.13% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
AURA Analyst Recommendation Trends
Rating
May 25
Jul 25
Aug 25
Sep 25
Nov 25
Strong Buy
16
9
10
5
8
Buy
4
3
4
2
2
Hold
2
1
0
0
0
Sell
1
0
0
0
0
Strong Sell
0
0
0
0
0
total
23
13
14
7
10
Each month's total comprises the sum of three months' worth of ratings.
AURA Financial Forecast
AURA Stock Forecast FAQ
What is AURA’s average 12-month price target, according to analysts?
Based on analyst ratings, Aura Biosciences Inc’s 12-month average price target is 19.33.
What is AURA’s upside potential, based on the analysts’ average price target?
Aura Biosciences Inc has 195.57% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is AURA a Buy, Sell or Hold?
Aura Biosciences Inc has a consensus rating of Strong Buy which is based on 4 buy ratings, 0 hold ratings and 0 sell ratings.
What is Aura Biosciences Inc’s price target?
The average price target for Aura Biosciences Inc is 19.33. This is based on 4 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $23.00 ,the lowest forecast is $13.00. The average price target represents 195.57% Increase from the current price of $6.54.
The highest analyst price target is $23.00 ,the lowest forecast is $13.00. The average price target represents 195.57% Increase from the current price of $6.54.
What do analysts say about Aura Biosciences Inc?
Aura Biosciences Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 4 Wall Streets Analysts.
How can I buy shares of AURA?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.